Janssen Pharm. N.V. v. Teva Pharm. USA, Inc., No. 08-1594

In a patent case involving a method for treating Alzheimer's disease and related dementias, district court's conclusion that the claims of the patent '318 were invalid is affirmed as the patent's description of using galantamine to treat the disease does not satisfy the enablement requirement because the patent application did not establish utility.     

Read Janssen Pharm. N.V. v. Teva Pharm. USA, Inc., No. 08-1594

Appeal from:  United States District Court for the District of New Jersey

Decided September 25, 2009

Judges

Before Mayer, Gajarsa, and Dyk, Circuit Judges

Opinion by Dyk, Circuit Judge.   

Counsel

For Appellant:  George F. Pappas, Covington & Burling LLP

For Appellee:  William A. Rakoczy, Rakoczy Molino Mazzochi Siwik LLP; George C. Lombardi, Winston & Strawn LLP